This page provides a comprehensive investment landscape analysis for amyloid-targeted therapeutics in Alzheimer's disease and related neurodegenerative conditions. Amyloid-beta (Aβ) accumulation is a hallmark pathological feature of Alzheimer's disease, and therapeutic approaches targeting amyloid represent the largest segment of the AD therapeutic pipeline. [1]
This analysis is based on clinical trial data from the NeuroWiki Clinical Trials Index, last updated 2026-03-12.
| Metric | Value |
|---|---|
| Total tracked amyloid-related trials | 667 |
| Active trials (recruiting/active/not-yet-recruiting) | 164 (24.6%) |
| Completed trials | 316 (47.4%) |
| Terminated/Withdrawn | 58 (8.7%) |
| Unknown status | 119 (17.8%) |
| Category | Trial Count | Share |
|---|---|---|
| Active | 164 | 24.6% |
| Recruiting | 99 | 14.8% |
| Not Yet Recruiting | 35 | 5.2% |
| Active Not Recruiting | 30 | 4.5% |
| Historical | 503 | 75.4% |
| Completed | 316 | 47.4% |
| Terminated | 36 | 5.4% |
| Withdrawn | 21 | 3.1% |
| Unknown | 119 | 17.8% |
| Phase | Trial Count | Share |
|---|---|---|
| Early Phase 1 | 9 | 1.3% |
| Phase 1 | 53 | 7.9% |
| Phase 1/Phase 2 | 11 | 1.6% |
| Phase 2 | 63 | 9.4% |
| Phase 2/Phase 3 | 5 | 0.7% |
| Phase 3 | 36 | 5.4% |
| Phase 4 | 7 | 1.0% |
| Not Applicable/NA | 483 | 72.4% |
Amyloid-targeted therapeutics can be categorized by their mechanism of action:
The largest mechanism category includes antibodies designed to bind and clear amyloid-beta plaques or soluble oligomers.
Key Programs:
Small molecules designed to prevent the formation of or break down amyloid oligomers and plaques.
Key Programs:
Beta-secretase (BACE) inhibitors block the initial cleavage of APP to produce Aβ.
Note: Several BACE inhibitors have failed in late-stage trials due to safety concerns (verubecestat, atabecestat, CNP520).
Modulators of the gamma secretase enzyme that shift Aβ production toward shorter, less aggregation-prone isoforms.
Key Programs:
Active immunization approaches to induce anti-Aβ antibody production.
Key Programs:
Approaches to enhance the clearance of Aβ through enzymatic degradation or cellular clearance mechanisms.
Diagnostic agents for amyloid plaque imaging:
| Sponsor | Trial Count |
|---|---|
| Institute for Neurodegenerative Disorders | 11 |
| National Taiwan University Hospital | 10 |
| Chang Gung Memorial Hospital | 9 |
| Washington University School of Medicine | 9 |
| University of Pittsburgh | 8 |
| Massachusetts General Hospital | 8 |
| Sponsor | Trial Count |
|---|---|
| Eli Lilly and Company | 9 |
| Affiris AG | 8 |
| Pfizer | 6 |
| Cyclo Therapeutics, Inc. | 6 |
| Eisai | 5 |
| Biogen | 4 |
| Roche | 4 |
| Novartis | 3 |
| AstraZeneca | 2 |
The amyloid therapeutic space has consolidated following the FDA approvals of Leqembi and Donanemab. Investment is shifting toward:
For current clinical trials targeting amyloid-beta and related pathways in Alzheimer's disease, see:
Clinical trial data from NeuroWiki Clinical Trials Index, updated 2026-03-12. See also:. ClinicalTrials.gov Alzheimer's Trials. 2026. ↩︎